Granowitz Craig B 4

What Happened
Craig B. Granowitz, Senior Vice President and Chief Medical Officer of Lexicon Pharmaceuticals (LXRX), was granted two derivative awards on February 12, 2026 totaling 866,530 restricted stock units (RSUs): 346,610 RSUs and 519,920 RSUs. Both awards were reported at $0.00 per share (RSUs are contingent rights to receive common stock rather than an open‑market purchase).

Key Details

• Transaction date: February 12, 2026; Report filed: February 17, 2026 (filing is timely given Feb 16 federal holiday).
• Award amounts and price: 346,610 RSUs @ $0.00 and 519,920 RSUs @ $0.00 (total 866,530 RSUs).
• Vesting: Per footnote, each RSU represents a right to one share (F1). RSUs vest 1/3 of the shares on February 28 of each of the three years following the year of grant (F2).
• Shares owned after transaction: Not provided in the data supplied.
• Other footnote: F3 describes an option vesting schedule (25% after one year then monthly thereafter); that appears to refer to options generally and does not apply to these RSU awards.

Context
RSUs are a form of compensation that convert into actual shares only as they vest; these awards do not represent an immediate purchase or sale of shares. Such grants are common for executive pay and are primarily a retention/incentive tool; they can lead to future dilution as they vest and are settled. No sale or exercise was reported in this filing.